DYRK1A and diabetes mellitus: Notably, a recent study has highlighted the significance and versatility of DYRK1A by showing that inhibition of DYRK1A by harmine increases human pancreatic β-cell proliferation through the modulation of NFAT signaling (Wang et al., 2015), indicating a new therapeutic approach for diabetes.